about
Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison.Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes.Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes.Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE TrialsAtherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 DiabetesAcute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 DiabetesRetinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 DiabetesEffects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trialsWhat have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortalityThe Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 DiabetesExploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 DiabetesPreventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline DataSerum Uromodulin Predicts Less Coronary Artery Calcification and Diabetic Kidney Disease Over 12 Years in Adults With Type 1 Diabetes: The CACTI Study
P50
Q47630310-EA2921F0-644F-4E72-BE05-A6C66DCA3293Q47887530-C53A4CAC-D685-4BB7-8602-1D130A3077F9Q48143838-1612538C-0C87-4483-9A5D-7A4C09B77E5AQ50043741-A0C46204-D2E8-4060-A8D4-07074D01FB0DQ57026286-BC382992-B330-470D-942A-B54B1469C071Q57054479-B7885942-DEE5-47DD-AAF7-5E2BA6DAC233Q89239968-99572CD0-9822-4607-AD92-E1278DD2D015Q90316001-9E16CBBC-1C90-4AE4-BBED-1BF8E66F32CCQ90821748-03AE6D19-D333-466F-B6D1-19DCD0959AD8Q91720442-6F15FBAD-9286-4CAC-AF97-8FA2F5E1232EQ91818499-87D38DD8-A7DD-430A-B006-ABEB28851329Q92351318-398AC897-630E-4664-AC47-6880B86960DAQ92608059-EF139BB9-730D-4B81-84CD-B3F1C58F769BQ92666069-C96912B0-DC09-42A3-9736-7D130CC4F7FDQ93349652-B7E3B777-72D8-44F2-AE53-2C1E365EFAAC
P50
description
researcher
@en
name
David Z I Cherney
@en
type
label
David Z I Cherney
@en
prefLabel
David Z I Cherney
@en
P31
P496
0000-0003-4164-0429